Polomar Health Services Reports 22,000% Q1 Revenue Growth, Narrowed Net Loss
Summary
Polomar Health Services reported Q1 2026 revenue of $1.01 million, a 22,000% increase year-over-year, and significantly narrowed its net loss to $(25.4K) from $(456.9K) in the prior year, with diluted EPS improving to $(0.00). These positive financial results are part of the same 10-Q filing that also disclosed a major lawsuit claiming over $20 million in damages and a $9.7 million write-down of intellectual property to zero. The filing intensified concerns about the company's ability to continue as a going concern. While the operational improvements and revenue growth are notable, they are heavily overshadowed by the severe legal and financial challenges, which are many times larger than the company's current market capitalization. The company plans to launch new products, including inhaled sildenafil, metformin gummies, and eletriptan, in late Q2 through Q4 2026.
At the time of this announcement, PMHS was trading at $0.08 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $0.07 to $960,000.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.